Literature DB >> 21062241

Cancer vaccines in phase II/III clinical trials: state of the art and future perspectives.

Sara Cecco1, Elena Muraro, Elisa Giacomin, Debora Martorelli, Renzo Lazzarini, Paolo Baldo, Riccardo Dolcetti.   

Abstract

The topic of this review covers a very important branch of cancer research, cancer vaccination. The growing knowledge in tumor immunology has evolved rapidly, starting from nonspecific generic stimulation of the immune system to more specific approaches based on the availability of tumor antigens. The review covers molecular and cell biology, and pharmaceutical technology of cancer vaccines. Particularly, it is aimed at highlighting the results of cancer vaccines from phase II and III clinical trials, an issue that is of relevance to better understand how cancer vaccines can successfully complement antitumor therapy, including conventional chemotherapy and the recently developed target-based drugs.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21062241     DOI： 10.2174/156800911793743664

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN： 1568-0096            Impact factor:   3.428


  14 in total

Review 1.  Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling.

Authors:  Helen Y Wang; Rong-Fu Wang
Journal:  Adv Immunol       Date:  2012       Impact factor: 3.543

Review 2.  Immunotherapy for esophageal squamous cell carcinoma: a review.

Authors:  Kosaku Mimura; Leo Yamada; Daisuke Ujiie; Suguru Hayase; Takeshi Tada; Hiroyuki Hanayama; Aung Kyi Thar Min; Masahiko Shibata; Tomoyuki Momma; Zenichiro Saze; Shinji Ohki; Koji Kono
Journal:  Fukushima J Med Sci       Date:  2018-07-27

Review 3.  Immune targets and neoantigens for cancer immunotherapy and precision medicine.

Authors:  Rong-Fu Wang; Helen Y Wang
Journal:  Cell Res       Date:  2016-12-27       Impact factor: 25.617

Review 4.  Successes, failures and new perspectives of idiotypic vaccination for B-cell non-Hodgkin lymphomas.

Authors:  Elena Muraro; Debora Martorelli; Riccardo Dolcetti
Journal:  Hum Vaccin Immunother       Date:  2013-02-13       Impact factor: 3.452

Review 5.  Immunomodulatory Nanosystems.

Authors:  Xiangru Feng; Weiguo Xu; Zhongmin Li; Wantong Song; Jianxun Ding; Xuesi Chen
Journal:  Adv Sci (Weinh)       Date:  2019-06-21       Impact factor: 16.806

Review 6.  Current status of cancer immunotherapy for esophageal squamous cell carcinoma.

Authors:  Koji Kono; Kousaku Mimura; Reo Yamada; Daisuke Ujiie; Suguru Hayase; Takeshi Tada; Hiroyuki Hanayama; Aung Kyi Thar Min; Masahiko Shibata; Tomoyuki Momma; Zenichirou Saze; Shinji Ohki
Journal:  Esophagus       Date:  2017-11-27       Impact factor: 4.230

7.  Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens.

Authors:  Koji Kono; Hisae Iinuma; Yasunori Akutsu; Hiroaki Tanaka; Naoko Hayashi; Yasuto Uchikado; Tsuyoshi Noguchi; Hideki Fujii; Kota Okinaka; Ryoji Fukushima; Hisahiro Matsubara; Masaichi Ohira; Hideo Baba; Shoji Natsugoe; Seigou Kitano; Kazuyoshi Takeda; Koji Yoshida; Takuya Tsunoda; Yusuke Nakamura
Journal:  J Transl Med       Date:  2012-07-09       Impact factor: 5.531

Review 8.  Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein-Barr-virus-driven disorders.

Authors:  Debora Martorelli; Elena Muraro; Anna Merlo; Riccardo Turrini; Damiana Antonia Faè; Antonio Rosato; Riccardo Dolcetti
Journal:  Clin Dev Immunol       Date:  2012-01-29

9.  Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer.

Authors:  Wataru Obara; Fuminori Sato; Kazuyoshi Takeda; Renpei Kato; Yoichiro Kato; Mitsugu Kanehira; Ryo Takata; Hiromitsu Mimata; Tamotsu Sugai; Yusuke Nakamura; Tomoaki Fujioka
Journal:  Cancer Sci       Date:  2017-06-23       Impact factor: 6.716

Review 10.  Current status of cancer immunotherapy.

Authors:  K Kono
Journal:  J Stem Cells Regen Med       Date:  2014-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.